JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients.
Florensa
L
L
Bellosillo
B
B
Besses
C
C
Puigdecanet
E
E
Espinet
B
B
Pérez-Vila
E
E
Longarón
R
R
Vilà
R M
RM
Solé
F
F
Serrano
S
S
D001792:Blood Platelets / Q000201:enzymology / Q000473:pathology; D019070:Cell Lineage; D004252:DNA Mutational Analysis; D015672:Erythroid Precursor Cells; D006098:Granulocytes / Q000201:enzymology / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2; D022423:Myeloid Cells / Q000201:enzymology* / Q000473:pathology; D017354:Point Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D013920:Thrombocythemia, Essential / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology
D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2